Wall Street brokerages expect that Coherus Biosciences Inc (NASDAQ:CHRS) will report $93.58 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Coherus Biosciences’ earnings, with the highest sales estimate coming in at $95.01 million and the lowest estimate coming in at $91.30 million. The firm is expected to announce its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Coherus Biosciences will report full-year sales of $323.86 million for the current year, with estimates ranging from $315.40 million to $340.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $404.37 million, with estimates ranging from $387.10 million to $440.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Coherus Biosciences.

Coherus Biosciences (NASDAQ:CHRS) last released its earnings results on Thursday, August 1st. The biotechnology company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.40. The company had revenue of $83.43 million during the quarter, compared to the consensus estimate of $81.05 million.

Several research firms have recently commented on CHRS. Barclays set a $30.00 price target on shares of Coherus Biosciences and gave the company a “buy” rating in a report on Friday, June 21st. Zacks Investment Research raised shares of Coherus Biosciences from a “hold” rating to a “strong-buy” rating and set a $23.00 price target for the company in a report on Friday, July 12th. BidaskClub lowered shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Friday, July 19th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target (up from $28.00) on shares of Coherus Biosciences in a report on Friday, August 2nd. Finally, ValuEngine lowered shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 17th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $29.57.

Shares of NASDAQ CHRS traded down $0.56 during midday trading on Thursday, hitting $19.15. The company’s stock had a trading volume of 1,166,777 shares, compared to its average volume of 939,569. Coherus Biosciences has a 1-year low of $8.32 and a 1-year high of $23.43. The business has a fifty day simple moving average of $19.67. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -5.95 and a beta of 3.10.

In other Coherus Biosciences news, Director James Healy sold 257,870 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $20.69, for a total transaction of $5,335,330.30. Following the completion of the transaction, the director now directly owns 92 shares of the company’s stock, valued at approximately $1,903.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Vincent R. Anicetti sold 2,500 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $19.20, for a total transaction of $48,000.00. The disclosure for this sale can be found here. Insiders sold a total of 1,176,724 shares of company stock valued at $25,365,332 over the last ninety days. Company insiders own 18.20% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CHRS. Aperio Group LLC acquired a new position in Coherus Biosciences during the 2nd quarter valued at about $80,000. Legal & General Group Plc lifted its stake in shares of Coherus Biosciences by 12.3% in the 4th quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 998 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Coherus Biosciences in the 1st quarter worth approximately $108,000. Bank of Montreal Can acquired a new stake in shares of Coherus Biosciences in the 2nd quarter worth approximately $114,000. Finally, BNP Paribas Arbitrage SA lifted its stake in shares of Coherus Biosciences by 107,870.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,797 shares of the biotechnology company’s stock worth $147,000 after acquiring an additional 10,787 shares during the period. 99.18% of the stock is owned by hedge funds and other institutional investors.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Featured Story: What is Cost of Goods Sold (COGS)?

Get a free copy of the Zacks research report on Coherus Biosciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.